12:00 AM
Oct 06, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen dependent kinase 3 (GSK3); dyskerin pseudouridine synthase 1 (DKC1)


INDICATION: Dyskeratosis congenita

Patient sample and cell culture studies suggest GSK3 inhibitors could help treat dyskeratosis congenita, which is caused by mutations in DKC1 or other genes that result in shortened telomeres, dysfunction in stem cell proliferation, abnormal skin and nails, intestinal...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >